KBC Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

KBC Group’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$128K	Buy	1,994 +1,288	+182%	+$66.8K	﹤0.01%	1270
2026 Q1	$34K	Buy	+706	New	+$31.3K	﹤0.01%	1767

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

KBC Group's KNSA Position: Q2 2026 in Review

KBC Group increased its Kiniksa Pharmaceuticals (KNSA) stake by 182% in Q2 2026, buying an estimated $66.8K and bringing the position to 1,994 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #1270.

KBC Group first reported a position in KNSA in Q1 2026 and has held it in 2 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

KBC Group held 1,994 shares of Kiniksa Pharmaceuticals worth $128K as of Q2 2026.
KBC Group bought 1,288 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $66.8K.
Kiniksa Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1270 holding.
KBC Group first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.